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Older adults with cancer are more likely to have worse clinical outcomes than their 
younger counterparts, and shared decision-making can be difficult, due to both 
complexity from adverse ageing and under-representation in clinical trials. Geriatric 
assessment (GA) has been increasingly recognised as a predictive and prehabilitative 
tool for older adults with cancer. However, GA has been notoriously difficult to 
implement in oncological settings due to workforce, economic, logistical, and practical 
barriers. We aimed to review the heterogenous literature on implementation of GA in 
oncology settings to understand the different implementation context configurations of 
GA and the mechanisms they trigger to enable successful implementation. A 
systematic realist review was undertaken in two stages: i) systematic searches with 
structured data extraction combined with iterative key stakeholder consultations to 
develop programme theories for implementing GA in oncology settings; ii) synthesis 
to refine programme theories. Medline, Embase, PsycInfo, Cochrane Library, 
CINAHL, Web of Science, Scopus, ASSIA, Epistemonikos, JBI Database of 
Systematic Reviews and Implementation Reports, DARE and Health Technology 
Assessment were searched. Four programme theories were developed from 53 
included articles and 20 key stakeholder consultations addressing the major barriers 
of GA implementation in oncology practice: time (leveraging non-specialists), funding 
(creating favourable health economics), practicalities (establishing the use of GA in 
cancer care), and managing limited resources. We demonstrate that a whole system 
approach is required to improve the implementation of GA in cancer settings. This 
review will help inform policy decisions regarding implementation of GA and provide a 
basis for further implementation research.   
 







Older adults with cancer generally experience worse outcomes compared to younger 
adults, including increased post-operative complications, length of hospital stay, 
chemotherapy toxicity, and discharge to dependent care settings (1-3). Age-related 
cognitive issues and the accrual of co-morbidities, medications and functional deficits, 
creates complexity (4-6). This makes shared decision-making between the patient and 
cancer multi-disciplinary team (MDT) more difficult, compounded by 
underrepresentation of older adults in clinical trials (7). Undertreatment (e.g. 
inappropriate best supportive care) or overtreatment (e.g. avoidable post-treatment 
morbidity and mortality) is possible, although older adults can tolerate and benefit from 
cancer treatments when appropriately selected (8). The clinician’s recommendation is 
a significant factor in treatment acceptance (9) and the use of chronological age as a 
proxy for health status is associated with worse patient outcomes (10-12).  
 
To enhance decision-making, international guidelines from authoritative bodies, 
including the American Society of Clinical Oncologists (ASCO) and International 
Society of Geriatric Oncology, recommend pre-treatment geriatric assessment (GA) 
for older adults (13, 14). GA has evolved in oncology from comprehensive principles 
employed by inpatient geriatric medicine (15), to a more focussed cancer-specific GA 
(CSGA) and/or the use of short screening tools (e.g. G8) (16, 17). Traditional 
comprehensive GA (CGA) is a complex intervention most commonly defined as “a 
multidimensional, multidisciplinary process which identifies medical, social and 
functional needs, and the development of an integrated/co-ordinated care plan to meet 
those needs” (15). Systematic reviews have demonstrated that CGA improves 
mortality and function for older medical patients and orthopaedic patients admitted 
with hip fracture (18, 19). Evidence that CSGA models improve outcomes are lacking. 
One randomised controlled trial (RCT) demonstrated feasibility (20). Another RCT was 
negative for improved morbidity or mortality (21), although other protocols have been 
published (22). The current view of GA in oncology therefore focuses on its role in 
prognostication, rather than its therapeutic effectiveness as a complex intervention 
(13, 14). Even so, first principles suggest that identifying and acting on unknown 
vulnerabilities identified through CSGA will improve outcomes. Moreover, 
implementation issues within RCTs may limit their effectiveness (21).  
 
GA is notoriously difficult to implement in oncology with numerous barriers frequently 
cited, including workforce limitations (23), time, health economics, logistics, training, 
and practical concerns (24). International guidelines inadequately cover 
implementation details, which tend to focus on reducing time required to undertake 
GA by using brief instruments. Insufficient detail is provided on practical, technological, 
and logistical enablers and a more detailed analysis of implementation science in this 
setting is required (13, 14). We aimed to review the heterogenous literature on 
implementation of GA in oncology settings to understand the different implementation 
context configurations of GA and the mechanisms they trigger to enable successful 
implementation. A review of the implementation of GA in oncology settings is 





Realist review is a theory-driven approach designed to understand the contextual 
basis of success for complex interventions and their mechanisms (25-27). Given the 
heterogeneity of implementation literature regarding GA in oncology, realist review 
was selected to explore the contexts, mechanisms and outcomes of GA 
implementation in this setting. The study protocol for this review was registered with 
PROSPERO (CRD42019156058) (28). The review meets the Realist And Meta-
narrative Evidence Syntheses: Evolving Standards (RAMESES) quality standards for 
realist review (29) (as documented in Supplementary Table 1) and is reported 
consistent with the RAMESES reporting guidelines (see Supplementary Table 2).  A 
two-stage approach was employed as we sought to focus on undertaking a robust 
systematic review, rather than an initial scoping review (29). 
 
Stage 1 – identifying the evidence relevant to GA and testing and refining the 
programme theories 
 
The primary ideas used to develop an intervention are termed the programme theories 
(25), which herein explain how to implement GA and achieve predictive and 
prehabilitative outcomes. The systematic review search strategy is outlined in Figure 
1 and inclusion and exclusion criteria are outlined in Figure 2. We undertook a single 
comprehensive search strategy, as opposed to an iterative search strategy, to ensure 
we fully understood the heterogenous research base and capture its diversity (30). 
Backward citation searching involved screening reference lists of relevant papers. 
Forward citation searching utilised Web of Science from the included studies after full 
text screening. 
 
Title and abstract screening were initially undertaken, followed by full text retrieval and 
review by GM. ‘If then’ statements were developed to document the various proposed 
situations towards successful GA implementation, which was supported by evidence 
drawn from the literature and our research group discussions (31). These statements 
generated programme theories linked to their respective proposed context, 
mechanism and outcomes for presentation and critique of plausibility and relevance 
by our research and steering groups. The quality of the evidence was determined by 
its ability to build or test the relevance of a programme theory, based on established 
methodology for realist reviews (29, 32-34). Data extraction followed for articles 
meeting this test of relevance and were primarily extracted by one team member (GM), 
with a random 25% independently checked by a second team member (AB). The data 
extraction process was form-based and included the programme theory that the article 
intended to support, the explicit or implicit conclusions made relevant to that theory 
and how the relevant evidence was organised (25). Data extraction included the study 
type, research methodologies and evidence to enable testing of programme theories. 
Following data extraction, relationships between context (e.g. organisational 
conditions), mechanisms (e.g. processes) and outcomes (e.g. all consequences and 
overall impact) were synthesised. Extracted information was organised into evidence 
tables with respect to different bodies of literature (e.g. implementation strategy, 
barriers and facilitators). Patterns related to context-mechanism-outcome 
configurations were themed across the evidence table. Finally, patterns were linked to 
form hypotheses.  
 
Key stakeholders were identified by peer recommendations from the professional 
network of the steering group, and then informal consultations were conducted to test 
and refine programme theories. Experts consulted from oncology MDTs included 
medical and clinical oncologists, surgeons, nurses, allied health professionals, MDT 
coordinators and a cancer business manager. Meetings with geriatricians, information 
technology (IT) staff and a clinical coding manager responsible for oncology services 
were also arranged. We presented stakeholders with proposed solutions to 
successfully implement GA and invited them to express how the contextual elements 
of GA may impact on the behaviours of those involved in its implementation. These 
consultations were documented by GM and used in combination with literature 
synthesis to support or refute programme theories. Data synthesis was further 
supported from a combination of individual reflection and group discussion in order to 
challenge the integrity of each theory, judge competing theories and compare the 
stated theory with actual practice. Data from the studies or stakeholder consultations 
were used to confirm, refute or refine the candidate theories. Alternative theories were 
sought where theories could not explain the data. 
 
Patient and public involvement 
Early findings were discussed with five patients in the context of their lived experience 
of cancer. Three of these patients were consulted on the configuration of a new GA 
service for oncology patients developed and operated by the lead author (GM). 
 
Ethical approval 
This realist review was part of a larger study which gained ethical approval by the 
Yorkshire and Humber – South Yorkshire Research Ethics Committee (19/YH/0382). 
Consultations with key stakeholders were not deemed to be research. Hull York 
Medical School ethical approval was gained prior to the start of the study. 
 
Stage 2 – analysing and synthesising evidence to test the proposed programme 
theories 
 
Following the completion of preliminary mapping of evidence into tables, the steering 
group was consulted. This group consisted of trans-disciplinary experts including 
oncologists, palliative care physicians, mixed-methodology researchers, statisticians, 
sociologists and systems thinking academics. The findings were discussed, and the 
resultant hypotheses were confirmed or rejected. Confirmed hypotheses were used 
as synthesised statements of context, mechanism, outcome narratives along with their 
supporting evidence. The process of analysis, synthesis and discussion was iterative 
in order to reach sufficient refinement of programme theories towards developing a 
new system for optimisation and predictive assessment of older adults with cancer. 
 
Results 
After deduplication of articles, 5,458 describing GA were screened and 214 were 
included in the review (Figure 3). Backward citation searching identified a further two 
articles and forward citation searching three articles. Twenty key stakeholder 
consultations were undertaken. Fifty-three articles were selected that provided 
sufficient detail on implementation of GA. Twenty-seven programme theories were 
initially developed from the 53 articles, which were consequently expressed as four 
programme theories addressing the major barriers in GA implementation in oncology 
practice: i) workload (leveraging non-specialists); ii) funding (creating favourable 
health economics); iii) practicalities (establishing the use of geriatric assessment in 
cancer care); and iv) resources (managing limited resources). Supplementary Table 
3 summarises the 53 included studies, their study designs and major findings. Table 
1 summarises the four programme theories linked to relevant studies and includes 
citations to the studies that helped generate them, in order to make the following text 
more readable, which also integrates insights from key stakeholder consultations and 
reflection. Figure 4 presents a conceptual framework for implementing GA in 
oncology. 
 
Programme theory 1: leveraging non-specialists  
Protocolised organisational structure 
GA is a complex intervention with indications, benefits, and alternatives, although it is 
frequently viewed as an assessment undertaken solely by geriatricians. Protocols for 
the use of GA within the cancer MDT can be constructed, which can help GA to be 
viewed as a complex intervention that can benefit oncological care. This view can help 
cancer specialists better appreciate the holistic value of GA, so that they can focus on 
cancer diagnosis and treatment, knowing that geriatric issues will be covered at some 
point, and vulnerabilities identified. 
 
Role of the geriatrician 
 
The role of the geriatrician is frequently identified by two extremes: i) reliance on 
geriatrician-led oncology services or Geriatric Oncology Programmes (GOPs); or ii) 
patient-led, CSGA with referrals to other services, including geriatric medicine. A GA 
can be undertaken by non-geriatricians, with careful protocolisation and 
systematisation within the host organisation. Geriatricians should be considered a 
scarce resource, as national workforce shortages to meet current and emerging 
healthcare demands are evident (35, 36). Implementation configurations which 
consider this real barrier therefore seem favourable and progressive. GA results can 
drive protocolised referrals to other healthcare professionals including allied health 
professionals (e.g. dieticians), geriatric medicine, and external services (e.g. social 
services). This implementation strategy reduces the number of consultations 
geriatricians have to undertake within cancer services, whilst enabling them to focus 
on the most complex patients. 
 
Patient self-report   
 
Patient self-report of GA either remotely or otherwise independently from the clinician 
has demonstrated feasibility. Not all patients will be capable of self-reporting, therefore 
systems must be in place to fall back to clinician-led reporting. This also requires 
psychometrically validated instruments, which are suitable for patient self-report 
wherever possible. Remote self-reporting can occur through paper-based methods 
(e.g. post) or digitally (e.g. mobile devices). An outpatient area can also be used, with 
the advantage of assistance being available if necessary. This can reduce the clinical 
time required to administer the assessment. Digital methods also offer more efficient 
capture of information and the potential to automate the processing of data. Digitalised 
remote completion may involve modern communication channels, including email, 
short message service, and push notifications, which save paper and offer 
environmental advantages. The process of self-reporting is widely acceptable to older 
patients and assistance is not required in the majority; therefore, it removes an 





Time is a scarce resource and a frequently cited barrier for cancer specialists. A 
substantive GA has healthcare provider components, including cognitive screening, 
co-morbidities assessment, medication review, and physical examination. However, 
this can be protocolised, systematised, and rationalised for outsourcing to trained staff 
other than physicians. Clinicians are often competing against overbooked clinics, 
frenetic MDT meetings, inpatient reviews, operating lists, and other service-critical 
activities. Leveraging an alternative workforce therefore reduces implementation time 
and subsequently cost. Opportunities exist to capitalise on emerging roles (e.g. 
physician associates) to undertake GA. Identifying the training opportunities, 
continuing professional development and support structures to create, develop, and 
sustain these positions is key. 
 
Assessment-guided care processes 
 
GA can guide subsequent care processes by identifying opportunities to refer to other 
healthcare professionals (e.g. dietetics), according to local service configurations and 
availability. Where referrals cannot be fulfilled (e.g. they are unavailable or have no 
capacity), there is an opportunity to collect important data on unmet needs. This can 
be used to drive business cases for service improvement, so could be viewed as a 
facilitator. Establishing assessment-guided care processes may create favourable 
networks, which can sustain conditions for implementation of GA. The concept of 
networks and their feedback loops is derived from complex adapting systems (CAS) 
theory, which has been applied to implementation science (37). CAS theory considers 
individual agents (e.g. cancer MDT, GA service, general practitioner) as a collection 
of dynamic, self-similar entities which are adaptive (37). Over time a degree of mutual 
dependency upon referrals can be anticipated, leading to the emergence of 




Recommendations made to cancer specialists from a GA team are not always 
implemented. There may be legitimate reasons, although some cases may be from 
lack of insight into their benefits. Where GA-guided referrals are made by clinical staff 
other than the cancer specialist, protocolisation can be established to autonomise the 
professional(s) undertaking a GA. The same professional(s) making the 
recommendations can take personal responsibility for their implementation and follow-
up, which may improve adherence to GA-guided recommendations. This 
autonomisation also reassures the cancer MDT that these referrals will be handled 
and helps to leverage the expertise of non-specialists. 
 
Programme theory 2: creating favourable health economics 
 
Geriatric oncology programmes 
 
The ideal model of GA in cancer care is frequently cited as a formal Geriatric Oncology 
Programme (GOP). A GOP is geriatrician-led and generally well-integrated into cancer 
pathways with mature referral criteria and strategy. Other members of the geriatric 
medicine team (e.g. clinical nurse specialists and allied health professionals) have key 
positions and may co-lead aspects of the service. However, this model exhibits 
significant workforce and economic resources making implementation challenging. If 
organisations can operate a GOP, maximisation of sustainability should take 
precedence to fully embed the GOP within cancer care. This includes developing 
local/regional networks to enable full clinical governance of the GOP within cancer 
services, creating training opportunities (e.g. fellowships), leveraging inter-disciplinary 
skills and developing research studies. Generating high quality health economic data 
to demonstrate favourable outcomes helps build the case necessary to secure long-
term funding. Cancer clinicians would likely become dependent upon GOP services, 
leading to ongoing demand and therefore sustainability.  
 
Insurers and payers 
 
Insurers generally do not cover GA within oncology and often institutions underwrite 
this themselves. There are no national financial incentives within the UK to undertake 
GA as part of cancer care. Dialogue is therefore required with insurers and payers to 
convince them of the wider value of multidimensional predictive assessment and 
prognostication. This includes health economic impacts (e.g. reducing chemotherapy 
toxicity admissions), the pricing of insurance premiums (e.g. risk mitigation), hospital 
tariffs (e.g. improved clinical coding) and population health planning. New top-down 
opportunities can be recognised by key stakeholders to encourage the use of GA at a 
national level. 
 
Data and quality improvement 
 
The use of data can support the understanding of the positive effects that 
implementing GA can have on cancer services. For example, reduced chemotherapy 
toxicity rates following GA service introduction. Data-driven continuous quality 
improvement can be undertaken and used for health economic analyses, particularly 
cost consequence analysis. Service-level improvements can further improve clinical- 
and cost-effectiveness and generate the data needed to support sustainability. IT 
systems can be established to build real-time, searchable databases of structured 
local/regional data, with high granularity relevant to geriatric oncology. This also drives 
advanced predictive analytics, institutional case series and provides further data 




GA-guided interventions can also be delivered using IT. Smartphone and web 
applications and Internet of Things devices have demonstrated feasibility for the 
delivery and monitoring of GA-guided interventions at home. This can save the travel 
burden, costs, and environmental impacts of visits to local services and encourages 
patient independence. Clinicians can gain reassurance from community monitoring of 
vulnerable patients and acquire new insight into the biopsychosocial effects of cancer 
and its treatment. 
 
Programme theory 3: establishing the use of geriatric assessment in cancer care 
 
Cancer-specific geriatric assessment 
 
There is a lack of evidence regarding which tools to use within a CSGA. Whilst 
attempts have been made to reach international consensus, heterogeneous 
instruments are often recommended. This largely depends on the rationalisation for 
their selection (e.g. short time taken to complete) versus their underlying psychometric 
properties. Cancer-specific geriatric assessment was popularised by Hurria et al. (16) 
in 2005. Building on this principle and taking advantage of the numerous systematic 
reviews of psychometric instruments that have been published since, CSGA can be 
developed further. The outputs of the GA can be aligned to the prediction of outcomes 
or optimisation before cancer intervention. A synthesis of the best available 
psychometrically validated instruments appropriate to the patient population, the 
method of administration and the potential unmet needs (e.g. pain) of patients with 
cancer can be designed at national levels. Homogeneity of the CSGA process at the 
national level may facilitate meta-analysis of CSGA outcomes, something which has 
not yet been undertaken. Positive findings at this level may help convince some 
clinicians who are doubtful of the evidence behind GA in cancer care.  
 
 
Cancer multi-disciplinary team policy 
 
 
Cancer MDTs may have initial uncertainty about how best to use GA in their care 
pathways. There are two main strategies: reactive (i.e. the index clinician makes a 
referral to a GA service) and proactive (i.e. the GA service proactively screens cancer 
pathway outpatient lists). Even within a single cancer site MDT, two different strategies 
may be employed and the conversion rate to cancer from outpatient lists should be 
explored. This insight can be used to strategise selection of patients who will most 




Some cancer centres have such limited resources to undertake GA that a screening 
strategy should be considered. Screening can either help select which patients would 
benefit most from a GA or can be used as an independent decision-support tool. 
Where screening is undertaken, population-relevant screening tools with high 






The integration of a geriatrician within a cancer MDT is often favoured, although 
current workforce limitations make this an unscalable solution. The strategy of dual 
cancer-site and geriatric oncology MDTs has demonstrated feasibility in some studies 
but was thought to be logistically too difficult in our stakeholder consultations. In NHS 
cancer services, MDTs frequently run over lunchtime hours and back on to outpatient 
clinics. There is little scope within specialist’s timetables to attend another MDT and 
this also depends on geriatrician–leadership and a formal GOP being established. 
These dependencies make this proposition unscalable in many healthcare systems. 
However, GA findings can be summarised in ways that are suitable for non-
geriatricians, either using proformas or well-designed software. Summarised GA 
findings using accessible terminology can be integrated into MDT processes to 





There is lack of consensus between medical and surgical research groups regarding 
the use of GA in cancer care. A cohesive view of the cancer pathway and where GA 
fits is distinctly missing. At the local level, this consensus is vitally important so that 
GA can be used centrally by the MDT and made available to all patients who will likely 
benefit. The championing of GA by a local opinion leader can help to establish this 
consensus.  
 
Clinical staff education 
 
Rather than trying to train cancer specialists (e.g. surgeons and oncologists) in 
geriatric principles, brief educational interventions appear better suited. Alternatives 
include a geriatric rotation in higher specialist oncology training. These should 
encourage GA to be considered as both a shared-decision support tool (e.g. predictive 
assessment) and a complex intervention (e.g. through generating referrals). This is in 
keeping with national work in the NHS such as the UKs national Perioperative Quality 
Improvement Programme (38). The aim should be for members of the cancer MDT to 
better understand the role of GA in cancer care and promote embedding into routine 
practice at the level of the MDT. Furthermore, ancillary motivators can be conveyed to 
front-line clinicians, which include: i) reduction of potential medico-legal action; ii) 
continuous professional development; and iii) research opportunities, particularly in 
collaboration with geriatric specialists to promote inter-departmental cross-fertilisation. 
This can help establish new bottom-up incentives that can drive local adoption of GA 
in cancer MDTs. 
Patient education 
 
Patients may be unwilling to complete a GA when they have not been adequately 
briefed about its indications and benefits. There may be a role for brief educational 
interventions for patients (e.g. scripted face-to-face summarisation or audio-visual 
introduction). This may help to fully engage patients in the process and help them to 
become active participants, by realising the value in GA at the point in their care. 
 
Whole system approach 
 
The issues of GA in oncology practice are a whole system implementation problem 
and a higher-level approach is required (37). This may include quasi-autonomous non-
governmental organisation guidance (e.g. National Institute of Health and Care 
Excellence) and governmental lobbying by specialist interest groups (e.g. British 
Geriatrics Society, Geriatric Oncology Special Interest Group) and charitable 
organisations (e.g. Macmillan Cancer Support). This could help refocus the national 
care agenda for older adults with cancer and establish powerful facilitators to 
encourage national implementation. 
 
Programme theory 4: managing limited resources 
 
Timing of assessment 
 
Undertaken too late in the cancer pathway and the results of a GA are unlikely to be 
used in shared decision-making and opportunities for optimisation and prehabilitation 
are missed. Undertaken too early and there is a chance that older adults who have a 
symptomatic benign condition or a false positive on screening undergo a GA, which is 
not ultimately required for decision-making. The latter situation may be preferred as it 
affords the opportunity to identify general health vulnerabilities that can be addressed. 
In a reactive model, the ideal time to undertake GA is immediately after the index 
specialist review when cancer is suspected, and investigation continues. In a proactive 
model, screening of 2 Week Wait lists is possible, including inviting patients for GA 
before the index specialist review. However, this generates a risk of overloading the 
GA service and not targeting those most in need, who may enter the cancer pathway 
through other routes.   
 
Primary care integration 
 
A significant number of new patients enter a cancer pathway through referrals from 
primary care. This opens the possibility of undertaking GA at the point of referral. A 
deterioration in health of an older adult is an opportunity to undertake GA, even if 
cancer is eventually excluded. However, increasing the workload of general 
practitioners or straining primary care services is discouraged. To avoid unnecessary 
duplication of data collection or intervention during GA, there is scope for improved 
health data utilisation from primary care. Primary care electronic health records are 
rich in data and mining this information using new technologies is possible. For 
example, natural language processing can extract and summarise health care data in 
structured (e.g. height and weight) or unstructured (e.g. freetext) forms. Cancer 
specialists are unlikely to have sufficient resources to provide robust aftercare 
agreements for frail older adults returning to the community.  Primary care plays a role 
here, but robust longitudinal care coordination will be required to manage complex 
patients, ideally with a community geriatrician. Evolving services such as Integrated 




Locally or nationally set cancer pathway targets were identified as a significant 
competing barrier. However, these could be relaxed, or an exception agreed for older 
adults to undergo GA before decision-making. If the pressure to meet targets in the 





There is still an opportunity cost for IT infrastructure and mechanisms to accommodate 
patients who cannot use technology must be implemented. For a digital patent 
reported CSGA, the remainder of the clinical components could be integrated into 
routine oncology appointments, without the need for a formal GA service. There is 
some evidence that even a Timed Up and Go test can be predicted using a three-
question decision tree, although this remains to be prospectively validated (39). This 
movement appears to have driven the reductionism of CSGA and emphasis on using 




Physical space and logistics have also been cited as an implementation barrier. If 
outpatient space is limited for inter-professional teams, technology can also offer 
solutions. Professionals undertaking CSGA can consider the use of telephone, video, 
instant messaging and automated conversational agent consultations. These are 
particularly suited towards advice-based interventions undertaken by allied health 
professionals (e.g. pharmacists, dieticians, and social workers). The decreased 
reliance on face-to-face consultations, where appropriate, can also reduce perceived 





Where referrals to geriatrician-led services are required based on GA results, these 
can be integrated into existing structures (e.g.  geriatric day clinic). This can reduce 
the initial barriers of establishing a dedicated GOP and promotes inter-speciality cross-
fertilisation. Exploration of the individual capacity of specialties and services is 
important. Geriatricians may be able to accommodate referrals from cancer services 
within a few weeks. If early GA through a proactive model and/or the relaxation of 
cancer pathway targets for older adults can be negotiated, then existing geriatric 




We have systematically reviewed and synthesised evidence from 53 research articles 
and 20 key stakeholder consultations using realist methodology regarding the 
implementation of GA in oncology settings. We have developed four major programme 
theories based on the most commonly cited implementation barriers, namely limited 
workload capacity, absence of funding, uncertain practicalities and limited resources. 
For each of these programme theories we have attempted to outline enablers around 
themes that map to these barriers. Enablers include protocolisation of GA towards the 
generation of GA-guided interventions formulated as referrals to other services by 
clinically autonomous non-specialists. A GOP requires robust clinical governance and 
the development of training, research and health economic data to promote 
sustainability. Where geriatricians are unavailable to operate a GOP, referring to 
existing geriatrician-led services can promote favourable network formation 
Technology can be utilised to address workload, health economic and resource 
barriers. These enablers are the product of realist review using the available evidence, 
key stakeholder expertise and the authors’ reflections. 
 
Strengths of this review include the novelty of using realist synthesis in the systematic 
review of GA in oncology settings and, to the best of our knowledge, this is the first of 
its kind. The vast majority of systematic reviews concerning GA within oncological 
settings have focussed on effectiveness (64, 65). Because respected international 
organisations already endorse and use GA in oncology settings, we chose to focus on 
implementation. We made the assumption that GA is an evidence-based practice. 
Realist review was chosen to facilitate the combination of heterogeneous literature 
exhibiting a range of study types with real-life experience and reflection. The lead 
author (GM) has designed and operates a new GA-based service for cancer patients. 
This first-hand experience helps to contextualise literature findings, thereby making 
programme theories more generalisable towards clinical practice and the wider 
implementation science community. The iterative approach of the steering committee 
also improved sense-making of the limited implementation literature, noting the 
absence of ideal study types such as hybrid implementation-effectiveness trials (40). 
A robust systematic search strategy was undertake utilising a novel implementation 
filter designed by an information specialist (SG) to help identify relevant papers from 
a large literature base (>10,000 results). We avoided the need to exclude key MeSH 
terms (e.g. ‘geriatric assessment’) to reduce the abstract screening workload  (41). 
Limitations include those common to systematic reviews, including the search strategy 
employed and the heterogeneity of studies. The search strategy was not designed to 
encompass all diagnostic accuracy studies of screening tools used before GA, which 
have been subject to several systematic reviews (42). We also excluded studies solely 
focussing on healthcare education, as our search strategy was not developed to 
capture all healthcare education literature. Some studies may not have been analysed 
in our review, although, the large number of abstracts screened and our rigorous 
forward and backward citation searching strategy means that major implementation 
studies were unlikely to be missed.  
 
Zubair et al. (41) undertook a realist review of CGA in UK care homes and found that 
the effectiveness of CGA in this context requires three components: i) 
structured/standardised assessment; ii) MDT review; and iii) care delivery 
coordination. Similarly, we found that a protocolised assessment undertaken by non-
specialist staff with carefully summarised results integrated into a tumour-site specific 
MDT appears effective. Oncological care delivery co-ordination comes either from the 
integration of geriatrics into oncology (e.g. establishing a GOP) or from autonomising 




We have demonstrated that a whole system approach is required to improve the 
implementation of GA in cancer settings using four programme theories. At the 
service-level, utilisation of IT, leverage of non-specialist staff skills and the consensus 
of individual MDTs helps to view GA as a predictive optimisation tool. At the 
organisation level, recognition of the cost consequences of GA, such as medicolegal 
mitigation, research opportunities and data generation for service improvement 
provide top-down incentives for GA. Finally, insurers, payers, and regulators should 
make a clear declaration, either way, about the value of GA within cancer care. This 
review should help guide policy decisions regarding implementation of GA and provide 




Figure 1 – Systematic review search strategy  
Search strategy for systematic review. Abbreviations: GA = geriatric assessment. 
 
Figure 2 – Inclusion and exclusion criteria for systematic review 
 
Inclusion and exclusion criteria for studies retrieved using systematic review 
strategy. Abbreviations: GA = geriatric assessment. 
 
Figure 3 – Literature search Preferred Reporting Items for Systematic review 
and Meta-Analyses  
Literature search Preferred Reporting Items for Systematic review and Meta-Analyses 
diagram for the systematic review of eligible studies. 
 
Figure 4 – Conceptual framework for implementing geriatric assessment in 
oncology practice.  
 
Summary of the key concepts for implementation of geriatric assessment in oncology 







Theme Context-mechanism-outcome References 
   
Programme theory 1 – leveraging non-specialists time 
 
Time is frequently cited as a major barrier to implementing GA in oncology care, although certain implementation configurations 




The process of undertaking GA can be delegated away from cancer specialists within a 
protocolised organisational structure. This can help to establish the indications, benefits, 
and alternatives of GA within the cancer multi-disciplinary team.  
 
(43-61) 
Role of the geriatrician Processes and structures can be instituted (e.g. IT systems, protocolisation, and 
pathways) to enable non-geriatricians to undertake GA. This can help to generate 
efficient referrals to geriatricians to maximise their input as a scarce resource 
 
(23, 45, 47, 48, 
50, 53-69) 
 
Patient self-report  If patients can self-report (where able) as much of a GA as possible, either remotely or 
otherwise independently from the clinician, by using the best available psychometrically 
validated instruments for this method of administration, then the clinician time to complete 
the GA process can be reduced. However, where IT is utilised to offer patient-led geriatric 
assessments within a digital-first strategy (e.g. using mobile or tablet devices), processes 
must be instituted to fall back to clinician-led or paper-based alternatives to enable data 
capture from groups unable or unwilling to self-administer the assessment digitally 
 
(47, 61, 63, 70-
83) 
Workforce The protocolisation and systemisation of the healthcare provider components of a GA 
can be outsourced to trained staff other than physicians where time is a scarce resource. 
This can reduce the implementation time and cost, whilst also creating new roles and 
opportunities for an evolving workforce (e.g. physician associates, advanced nurse 
practitioners, and allied healthcare professionals) 
 
(53, 54, 56, 58-




Geriatric assessment-guided processes can be developed according to local service 
configurations and availability. This means that many of the recommendations of GA can 
be fulfilled by referring to allied health professionals and other specialist services creating 
a network effect and emergence of a complex adapting system 
 
 
(58, 60, 67, 85-
87) 
Autonomisation Processes (e.g. agreements, protocolisation, and pathways) can be established to 
autonomise the professional(s) undertaking a GA before cancer treatment. This means 
that the same professional(s) making the recommendations can take responsibility for 
their implementation and follow-up. 
(45, 46, 53-55, 
60, 62, 64, 74, 
86) 
 
Programme theory 2 – creating favourable health economics 
 
Cost is another frequently cited barrier to implementing GA in oncology care, although certain implementation configurations and 




There may be cases where organisations have sufficient resources (e.g. time, funding, 
and workforce) to establish a formal Geriatric Oncology Programme. In these cases, 
attempts should be made to embed local/regional networks to enable the programme to 
have full clinical governance, create training opportunities (e.g. fellowships), leverage 
inter-disciplinary skills, and recruit into research studies. This can ensure long-term 
incentives are created to maintain long-term funding. 
 
(58, 60, 61, 68, 
69, 81, 83, 84, 
88)  
Insurers and payers If insurers and payers can be convinced of the wider value of multidimensional predictive 
assessment and prognostication from the perspective of economics, including pricing of 
insurance premiums, hospital tariffs, and population health planning, then new top-down 
opportunities can be recognised for key stakeholders to encourage the use of GA. 
 
(54, 58, 60, 61) 
Business intelligence  GA-based services can be subjected to data-driven continuous quality improvement and 
health economic analysis. Service-level improvements can be made to improve clinical- 
and cost-effectiveness and build business cases for longer term, mainstream funding and 
therefore sustained implementation. IT systems can be established to build real-time, 
(51, 58, 60, 85, 
89, 90) 
searchable databases of structured local/regional data with high granularity relevant to 
geriatric oncology. This data can drive predictive analytics, institutional case series and 
business intelligence towards clinical treatment, research, and quality improvement. 
 
Information technology  If GA-guided interventions can be delivered using IT (e.g. mobile/web applications, 
Internet of Things devices), then some interventions can be delivered and monitored at 
home, saving the travel burden, costs, and environmental impacts of visits to local 
services and encouraging independence 
 
(81, 87) 
Programme theory 3 – establishing the use of geriatric assessment in cancer care 
 




geriatric assessment  
Lack of evidence and/or an international consensus often precludes the homogeneity of 
GA in oncology settings. However, CSGA can be undertaken utilising a synthesis of the 
best available psychometrically validated instruments appropriate to the patient 
population, the method of administration, and the potential unmet needs (e.g. pain and 
fatigue) of patients with cancer. The outputs of GA can therefore be aligned to prediction 
of outcomes or optimisation before cancer intervention. 
 
(47, 58, 64, 70, 
71, 73-76, 79, 91) 
Cancer multi-
disciplinary team policy 
If models of reactive (e.g. by referral) and proactive selection (e.g. screening of suspected 
cancer outpatient lists) for GA can be agreed within individual cancer multi-disciplinary 
teams, then GA can be used for patients most likely to benefit from its predictive and 
optimisation capabilities. 
 
(54, 56, 64, 81, 
82, 89, 92) 
Screening If cancer centres have limited resources to undertake GAs, then population-relevant 
screening tools with high diagnostic accuracy (e.g. G8) can be utilised either to identify 
patients potentially more in need of GA or as an independent decision-support tool. 
(23, 47, 49, 50, 
53, 54, 58, 62, 64, 
67, 69, 77, 81, 88, 
89, 92, 93)  
 
Clinician accessibility  Geriatricians cannot often be integrated within cancer multi-disciplinary team meetings to 
convey results of GA. However, summarised GA findings which are suitable for non-
geriatricians can be integrated into MDT processes to facilitate utilisation of results in 
clinical decision-making. 
 
(46, 48, 50, 52-
54, 58-62, 64-66, 
69, 84, 89, 92) 
 
Local champion If medical and surgical oncologists can be aligned by consensus and championed by a 
local opinion leader towards utilising GA at the level of the MDT, then the benefits of GA 
can be made available to all cancer patients. 
 
(23, 49-54, 60, 
61, 81, 94) 
 
Clinical staff education Brief educational interventions can encourage GA to be considered as both a shared-
decision support tool (e.g. predictive assessment) and a complex intervention (e.g. 
through generating referrals). This can enable members of the cancer MDT to better 
understand its role in cancer care and promote embedding of GA into routine practice. 
Furthermore, ancillary motivators can be conveyed to front-line clinicians including 
reduction of potential medico-legal burden, continuous professional development, and 
research opportunities. This can help establish new bottom-up incentives that can drive 
local adoption of GA in cancer multi-disciplinary teams. 
 
(46, 49, 50, 52, 
54, 58-61, 81, 83, 
88) 
  
Patient education Patients can undergo brief educational interventions (e.g. scripted face-to-face 
summarisation or audio-visual introduction) concerning the indications and benefits of GA 
in oncology settings. They may therefore be more likely to engage fully in the process and 
become active participants. 
 
(49, 58, 63, 72) 
Whole system 
approach 
A whole system approach can be considered, including local implementation champions, 
regional policies, quasi-autonomous non-governmental organisation guidance (e.g. 
National Institute of Health and Care Excellence) and governmental lobbying by specialist 
interest groups/medical organisations. This could help refocus the care agenda for older 
adult with cancer and powerful facilitators could be established to encourage national 
implementation 
(54, 58, 60, 61, 
81, 88) 
 
Programme theory 4 – managing limited resources 
 
Resources can be limited to undertake geriatric assessment in cancer care, although there are ways of managing this scarcity 
including: - 
 
Timing of assessment GA can occur early in the cancer pathway, immediately after the index clinical review. 
This enables the results of GA to be available to the cancer MDT for shared decision-
making and more time will become available within existing cancer pathway targets to 
enable prehabilitation 
 






Integration with primary care and community services can be improved, in terms of GA 
timing, health data utilisation, aftercare agreements and referral guidelines. The process 
of GA can therefore be streamlined and the challenges of the longitudinal care for the 
most frail and older adults can be improved 
 
(69, 81) 
Policy Locally or nationally set cancer pathway targets can be relaxed or an exception agreed 
for older adults to be allowed time to undergo GA before decision-making. This eliminates 
one-size-fits-all pathway configurations, which can be more accommodating for older 




(58, 64, 95) 
 
Information technology  If systems can be developed (e.g. cybernetics, automation, and algorithms) so that 
implementation cost (e.g. time, training, human resources, procurement) can be 
minimised, then GA can be embedded into routine oncology practice without the need for 
a separate geriatric oncology team.  
 
(23, 47, 50, 53-55, 
57-61, 63-65, 67, 
69, 72, 79, 81, 83, 




If outpatient space is limited for inter-professional teams, then increased use of phone, 
video, instant messaging and automated conversational agent consultations can be 
considered (e.g. pharmacy, nutrition, and social work interventions), which can also 
reduce travel burden, costs and environmental effects 
 
(81) 
Existing resources If referrals to geriatrician-led services are required based on GA results and these are 
integrated into existing structures (e.g. internal liaison, geriatric day clinic), then this 
reduces the initial barriers of establishing a dedicated geriatric oncology service and 
promotes inter-speciality cross-fertilisation 
(54, 58, 60, 61, 
65, 66, 68, 69, 81, 
84) 
 
Table 1 – Programme theories tested in the review  
The four programme theories with their sub-theories are presented. Abbreviations: GA = geriatric assessment; MDT = multi-


































Electronic databases were searched using their relevant control language from inception to July 2019 
 
Databases 
MEDLINE, Embase, and PsycInfo via OVID; The Cochrane Database of Systematic Reviews and 
Cochrane Central Register of Controlled Trials within the Cochrane Library; CINAHL via EBSCOhost, 
Web of Science Core Collection, Scopus, Applied Social Sciences Index and Abstracts (ASSIA) via 
ProQuest, Epistemonikos, JBI Database of Systematic Reviews and Implementation Reports, Database 
of Abstracts of Reviews of Effects, and Health Technology Assessment.  
 
Search terms 
For cancer: “cancer*”, “neoplas*”, “tumor*”, “tumour*”, “malignan*”, “carcinoma*”, “metasta*”, “oncolog*”, 
“leukemi*”, “leukaemi*”, “lymphoma*”, “myeloma*”, and “sarcoma*”. The Medical Subject Heading 
(MeSH) term “Neoplasms” was also used where possible, depending on the database.  
 
For geriatric assessment: MeSH terms “Geriatric Assessment” and “Health Services for the Aged”. The 
MeSH terms “Needs Assessment”, “Risk Assessment”, “Diagnostic Services”, "Health Services Needs 
and Demand", “Health Services”, "Delivery of Health Care", "Outcome and Process Assessment (Health 
Care)" were also combined with “geriatrics”. MeSH terms were ‘exploded’ (using the Ovid interface 
where appropriate). See Supplementary Data File 1 for full search strategies. 
 
Limits 
Limits were applied for adult humans in MEDLINE and to remove conference abstracts from Embase. 
Where >2,000 results were returned from a database using the above search strategy, attempt was 
made to filter the results using an implementation research filtering strategy devised by an Information 
Specialist (SG) based on similar systematic reviews. This was applied to the combined results from the 
MEDLINE, Embase, and PsycInfo via OVID and Scopus. This included the MeSH terms 
“Implementation Science”, “Organizational Innovation”, “Quality Improvement” and “Diffusion of 
Innovation”, combined with the keywords “barrier*”, “constraint*”, “facilitator*”, “enabler*”, “sustainability”, 
“feasibility”, “maintenance”, “acceptab*”, “appropriat*”, “uptake”, “embed*”, “adher*”, “usage”, 
“engagement”, “fidelity”, “Institutionalis*”, “institutionaliz*”, “implement*”, “dissemin*”, “adopt*”, 
“practice*”, “organi?ational change*”, “diffus*”, “quality improvement*”, “transform*”, “translat*”, 
“transfer*”, “sustainab*”, and “capacity”. Searches across all fields were also made for the terms (system* 
ADJ2 change*) in combination with MeSH terms and other keywords. Where databases returned <2,000 




































Inclusion criteria for research studies 
• Reported data from participants aged 65 and over 
• Participants had a diagnosis of cancer 
• Article focused on the implementation or use of GA 
 
Exclusion criteria for research studies 
• Reported data on implementation or use of GA in community, care of the elderly, orthogeriatric, 
and acute settings 
• Absent detail of the implementation strategies employed, barriers of implementation, facilitators 
of implementation, amount of infrastructure and human resources required or the satisfaction 
of patients undergoing the assessment process 
• Studies reporting the diagnostic accuracy of screening tools, unless screening was part of a 
relevant implementation strategy  
• Studies focussing solely on healthcare education 
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